Use of inhaled @entity288 for the prevention and/or treatment of XXXX in preterm @entity1 : a systematic review protocol.

@entity1 @entity2107 @entity23 @entity230 @entity288
BACKGROUND: Inhaled @entity230 have been studied for both prevention and treatment of @entity2107 ( @entity2107 ). Results have been inconsistent. Recently, a large @entity23 ( @entity23 ) has been reported. METHODS/DESIGN: We will perform a comprehensive systematic literature search for randomized and quasi-randomized controlled trials that studied the efficacy and safety of inhaled @entity288 administered to preterm @entity1 (22-36  weeks) for either the prevention or treatment of @entity2107 diagnosed by both clinical and physiological outcome criteria. We will assess potential risk of bias for each @entity23 meeting our selection criteria using the Cochrane risk of bias tool for RCTs. The primary outcome of interest will be mortality or @entity2107 or both at 28  days postnatal age or 36  weeks postmenstrual age. Pooled estimates will be calculated using RevMan software with a random effects model as primary analysis. We will assess the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. DISCUSSION: Meta-analytic estimates of eligible RCTs, potentially including a new large @entity23 , may significantly influence neonatal practice in the prevention and treatment of respiratory problems in preterm @entity1 . SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015019628.
